Wedbush analyst Laura Chico raised the firm’s price target on Vigil Neuroscience to $23 from $22 and keeps an Outperform rating on the shares. The firm noted that Sanofi’s $40M strategic investment in Vigil represents a ~100% premium to where shares previously closed, and extends Vigil’s cash runway into 2026, where it was previously into the second half of 2025, ahead of forthcoming iluzanebart data in ALSP, which is expected in Q3 of this year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil Neuroscience announces $40M investment from Sanofi
- Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
- These 2 ‘Strong Buy’ Penny Stocks Are Poised for a Massive Rally, Say Analysts
- Vigil Neuroscience to Present in Upcoming June Investor Conferences
- Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference